- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Sweet Corrosion Inhibition by CO Capture. (Pubmed Central) - Sep 3, 2022
The results showed an inhibition efficiency of the sweet corrosion process greater than 95%, and that the inhibition mechanism was different from the classic corrosion process in CO-free electrolytes. In this case, it was observed that the inhibitory capacity of the La cations is based on a CO-capture process and the precipitation of a barrier layer of lanthanum carbonate (La(CO)).
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda, NN1213 / Novo Nordisk
Trial completion: Phosphate Lowering in CKD Trial (clinicaltrials.gov) - Aug 26, 2022
P4, N=66, Completed,
This study may facilitate to optimize the synthesis design of phosphate multi-functional composites for low-carbon and sustainable treatment of industrial phosphate-containing wastes. Unknown status --> Completed
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Preclinical, Journal: Evaluation of cerium oxide as a phosphate binder using 5/6 nephrectomy model rat. (Pubmed Central) - Aug 10, 2022
Decreased body weight gain and increased water intake and urine volume in 5/6Nx rats were thought to be an effect of nephrectomy because these changes did not occur in sham operation rats. Additional investigations are needed to evaluate the longer-term safety and possible accumulation of cerium oxide in the body.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Review, Journal: Phosphate removal and recovery by lanthanum-based adsorbents: A review for current advances. (Pubmed Central) - Jun 29, 2022
This paper reviews research of phosphate adsorption on La-based adsorbents in different La forms, including lanthanum oxide/hydroxide, lanthanum mixed metal oxide/hydroxide, lanthanum carbonate, La, La-based metal-organic framework (La-MOF) and La-MOF derivatives...It should be carried out to further develop La-based materials with high adsorption capacity, good regeneration ability. Meanwhile, studies have been conducted on the reuse of phosphate after desorption, which needs more attention in future research.
- |||||||||| Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
Real-World Adherence and Persistence on Phosphate Binders Among Dialysis-Dependent Patients With Chronic Kidney Disease () - Mar 6, 2022 - Abstract #NKFSCM2022NKF_SCM_706;
Further studies are needed to determine the reasons for these findings on use of PB and its variation across different binders within the class. These studies could identify opportunities for better control of phosphate levels among patients with CKD.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Review, Journal: Lanthanum Carbonate Opacities-A Systematic Review. (Pubmed Central) - Feb 26, 2022
Stopping LC treatment or changing to an alternative phosphate binder prior to planned image studies can avoid diagnostic confusion. If this is not an option, knowledge of the presentation of LC opacities is important.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda, TheraSphere (yttrium 90 microspheres) / Boston Scientific
Review, Journal: New Kids on the Block: A Review of the Latest Iatrogenic Foreign Materials Seen in Gastrointestinal Specimens. (Pubmed Central) - Jan 18, 2022
Correct identification of these iatrogenic agents is important because the presence of some novel agents can explain the histopathologic findings seen in the background specimen, and specific novel agents can serve as diagnostic clues to prompt the pathologist to consider other important and related diagnoses. Awareness of even biologically inert agents is important for accurate diagnosis and to avoid unnecessary and expensive diagnostic studies.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Trial completion date: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (clinicaltrials.gov) - Jan 14, 2022
P4, N=44, Not yet recruiting,
Awareness of even biologically inert agents is important for accurate diagnosis and to avoid unnecessary and expensive diagnostic studies. Trial completion date: Jan 2023 --> Apr 2023
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Coupled catalytic dephosphorylation and complex phosphate ion-exchange in networked hierarchical lanthanum carbonate grafted asymmetric bio-composite membrane. (Pubmed Central) - Nov 11, 2021
The catalysis of para-nitrophenyl phosphates (pNPP) to paranitrophenol (pNP) in a sequential dephosphorylation by REMC offers an estimate of reaction kinetics and elucidates the underlying mechanism of improved phosphate selectivity in a multi-ionic environment. Furthermore, phosphate specificity, homogeneous binding capacity, reusability, and visual observation of REMC membrane saturation binding direct it's useful economic, industrial applications in aqueous phosphate contaminant removal, which could be beneficial for the active recovery of the aquatic ecosystem.
- |||||||||| Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
Review, Journal: Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality. (Pubmed Central) - Oct 27, 2021
Dialysis US: Spherix Global Insights, 2019]. Given a growing evidence base that the dominant mechanism of phosphate absorption is the intestinal paracellular pathway, new therapies are investigating ways to reduce phosphate levels by blocking absorption through the paracellular pathway.
- |||||||||| Tivicay (dolutegravir) / ViiV Healthcare
PK/PD data, Journal: Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions. (Pubmed Central) - Oct 22, 2021
This study examined how the pharmacokinetics of DTG are affected by co-administration with Al(OH), LaCO, and the polycation polymers bixalomer (Bxl) and sevelamer (Svl)...These comparisons also revealed a considerable reduction in the maximum concentration, suggesting that the interactions of these agents with DTG in the intestinal tract inhibit absorption of DTG. The above results demonstrate that Al(OH), LaCO, Bxl, and Svl affect the pharmacokinetics of DTG and indicate the need for caution when combining any of the above preparations with DTG.
- |||||||||| [VIRTUAL] Successful Treatment of Systemic Calcinosis in a Teenager on Hemodialysis () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2901;
Dialytic phosphate (P) clearance, and non-calcium(Ca), non-aluminum(Al) based binder use were maximized, using sevelamer and lanthanum carbonate...After 10 months, iv pamidronate was initiated to prevent further demineralization...Lanthanum is an effective metal Ca binder, but prolonged use may lead to accumulation and systemic deposition. The emergence of new P binders: ferric citrate, sucroferric oxyhydroxide, and bixalomer will offer exciting new treatment options.
- |||||||||| Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
[VIRTUAL] Real-World Use of Phosphate Binder Agents Among Dialysis-Dependent Patients with CKD in Medicare Fee-for-Service () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2171;
Binder use was reported in 60% of all outpatient dialysis months for patients in our study, suggesting that PBs may have been underutilized or required only intermittently. Further studies are needed to determine the reasons for gaps in PB use and to identify opportunities for control of phosphate levels among patients with DD ESRD.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
Clinical, Journal: Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. (Pubmed Central) - Sep 23, 2021
Whether this translates into beneficial clinical outcomes relevant to chronic-kidney disease-mineral and bone disorder warrants further investigation. Further study with a larger sample size is needed, but strict phosphate control shows promise for delaying progression of CAC in patients undergoing maintenance hemodialysis.
- |||||||||| TPOXX (tecovirimat) / SIGA Technologies
Trial completion date, Trial primary completion date: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (clinicaltrials.gov) - Sep 21, 2021
P4, N=44, Not yet recruiting,
Further study with a larger sample size is needed, but strict phosphate control shows promise for delaying progression of CAC in patients undergoing maintenance hemodialysis. Trial completion date: Sep 2022 --> Jan 2023 | Trial primary completion date: Sep 2022 --> Jan 2023
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Clinical, Review, Journal: Early gastric cancer with lanthanum deposition mucosa by endoscopic submucosal dissection: a case report and literature review. (Pubmed Central) - Sep 17, 2021
Lanthanum carbonate is used to prevent hyperphosphatemia in dialysis patients with chronic renal failure and generally recognized as poorly absorbed by the gastrointestinal tract...This case indicates the clinical significance of lanthanum deposition associated with gastric cancer. It is further required to evaluate more endoscopic images of the gastric mucosa, especially intramucosal cancer, with lanthanum deposition.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Deposition patterns of iatrogenic lanthanum and gadolinium in the human body depend on delivered chemical binding forms. (Pubmed Central) - Sep 3, 2021
The ratio-approach allows for the usage of the additionally generated Gd data, without detailed knowledge about possible GBCA applications. The significantly decreased Gd-to-La-ratio in the brain might be explained by the lanthanum being released and taken up as free La ion in the stomach that impedes a crossing of the blood-brain-barrier while the intravenously injected GBCAs might dechelate first when they have already crossed the blood-brain-barrier.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Effect of Lanthanum Carbonate on Blood Pressure in CKD. (Pubmed Central) - Aug 29, 2021
The significantly decreased Gd-to-La-ratio in the brain might be explained by the lanthanum being released and taken up as free La ion in the stomach that impedes a crossing of the blood-brain-barrier while the intravenously injected GBCAs might dechelate first when they have already crossed the blood-brain-barrier. No abstract available
- |||||||||| Review, Journal: Phosphate binders in chronic kidney disease: an updated narrative review of recent data. (Pubmed Central) - Aug 20, 2021
For this narrative review a PubMed searched was undertaken to identify new publications on phosphate binders that had been published between January 2015 and July 2019. The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Trial completion date, Trial primary completion date, Metastases: Different Effects of Non-calcium Phosphate Binders on Serum Calcium (clinicaltrials.gov) - Aug 18, 2021
P4, N=34, Completed,
The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters. Trial completion date: Jun 2015 --> Dec 2020 | Trial primary completion date: Jul 2013 --> Dec 2020
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Journal: Investigating coherent normalization and dosimetry for the 241Am-La K XRF system. (Pubmed Central) - Jul 22, 2021
Lanthanum (La) retention in bone has been shown to occur in individuals who are orally administered lanthanum carbonate (LaC), a drug to treat hyperphosphatemia...In addition, the dose delivered during a 2000 s measurement was determined using radiochromic film.Main The coherent normalization of La characteristic x-ray peaks showed to be independent of overlying tissue thickness, source-subject movement and bone radius, which indicates that this normalization procedure can correct for these factors. The equivalent skin dose and effective dose were 18.0 mSv and 3.2 μSv, respectively for a 5-year old child.Significance:While coherent normalization for the bone lead (Pb) and bone gadolinium systems have shown to be successful, we also report that this normalization procedure can correct for these interpatient variabilities in thein vivoAm-La K XRF K XRF system.
- |||||||||| Fosrenol (lanthanum carbonate) / Takeda
Clinical, Journal: Case report of lanthanum deposition in the esophagus. (Pubmed Central) - Jun 30, 2021
Although a few studies regarding lanthanum deposition in the stomach have been conducted, there are no reports on lanthanum deposition in the esophagus. This case suggests that the presence of longitudinal white plaques in the esophagus may indicate lanthanum deposition.
|
